PD-1/PD-L1-IN 3 (TFA)

PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases[1].

Product Specifications

UNSPSC

12352209

Target

PD-1/PD-L1

Type

Peptides

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pd-1-pd-l1-in-3-tfa.html

Purity

99.96

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

OC(C(F)(F)F)=O.O=C(N([C@H](C(N([C@H](C(N[C@H](C(N[C@](CSCC(N[C@H](C(N([C@H](C(N[C@H](C(N1CCC[C@]1(C(N[C@]([H])(C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C2=O)CO)=O)CC3=CNC4=CC=CC=C34)=O)C)=O)CC(C)C)=O)CC5=CN=CN5)=O)[H])=O)CC(N)=O)=O)C)C)=O)CC6=CC=CC=C6)=O)([H])C(NCC(N)=O)=O)=O)CCCNC(N)=N)=O)CCCC)C)=O)CCCC)C)[C@](N2)([H])CC7=CNC8=CC=CC=C78